Immunology 115:565–574PubMedCrossRef 27. Dan HC, Sun M, Kaneko S

et al (2004) Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279:5405–5412PubMedCrossRef 28. Lee JW, Choi JJ, Seo ES et al (2007) Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 46:941–947PubMedCrossRef 29. Kundu SD, Lee C, BIBW2992 manufacturer Billips BK et al (2008) The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 68:223–229PubMedCrossRef 30. Merrell MA, Ilvesaro JM, Lehtonen N et al (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix Ricolinostat molecular weight metalloproteinase activity. Mol Cancer Res 4:437–447PubMedCrossRef AZD1390 chemical structure 31. Luo JL, Maeda S, Hsu LC et al (2004)

Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6:297–305PubMedCrossRef 32. Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–466PubMedCrossRef 33. Ren T, Wen ZK, Liu ZM et al (2007) Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 6:1704–1709PubMedCrossRef 34. Linehan DC, Goedegebuure PS (2005) CD25+ CD4+ regulatory T-cells in cancer. Immunol Res 32:155–168PubMedCrossRef 35. Perrone G, Ruffini PA, Catalano V et al (2008) Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 44:1875–1882PubMedCrossRef 36. Martinez FO, Sica A, Mantovani A et al (2008) Macrophage activation and polarization. Front Biosci 13:453–461PubMedCrossRef Lumacaftor order 37. Marigo I, Dolcetti L,

Serafini P et al (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222:162–179PubMedCrossRef 38. Rodriguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222:180–191PubMedCrossRef 39. Kryczek I, Lange A, Mottram P et al (2005) CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 65:465–472PubMed 40. Li H, Fan X, Houghton J (2007) Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 101:805–815PubMedCrossRef 41. Haviv I, Polyak K, Qiu W et al (2009) Origin of carcinoma associated fibroblasts. Cell Cycle 8:589–595PubMed 42. Bhowmick NA, Chytil A, Plieth D et al (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848–851PubMedCrossRef 43. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4–10PubMedCrossRef 44.